In Vitro and in Vivo Analyses Reveal Profound Effects of Fibroblast Growth Factor 16 as a Metabolic Regulator*
- Ingrid C. Rulifson‡12,
- Patrick Collins§1,
- Li Miao‡,
- Dana Nojima§,
- Ki Jeong Lee¶,
- Miki Hardy§,
- Jamila Gupte‡,
- Kelly Hensley‖,
- Kim Samayoa‖,
- Cynthia Cam**,
- James B. Rottman‡‡,
- Mike Ollmann§,
- William G. Richards§§ and
- Yang Li‡3
- From the ‡Department of Cardiometabolic Disorders,
- the §Genome Analysis Unit,
- the ‖Department of Pathology, and
- the **Department of Comparative Animal Research, Amgen Inc., South San Francisco, California 94080,
- the ¶Genome Analysis Unit and
- the §§Department of Cardiometabolic Disorders, Amgen Inc., Thousand Oaks, California 91320, and
- the ‡‡Department of Pathology, Amgen Inc., Cambridge, Massachusetts 02142
- ↵2 To whom correspondence may be addressed: Dept. of Cardiometabolic Disorders, Amgen, Inc., 1120 Veterans Blvd., South San Francisco, CA 94080. Tel.: 650-244-2149; E-mail: ingridr{at}amgen.com.
- ↵3 To whom correspondence may be addressed: Dept. of Cardiometabolic Disorders, Amgen, Inc., 1120 Veterans Blvd., South San Francisco, CA 94080. Tel.: 650-244-2524; E-mail: yangl{at}amgen.com.
-
↵1 Both authors contributed equally to this work.
-
Edited by George M. Carman
Abstract
The discovery of brown adipose tissue (BAT) as a key regulator of energy expenditure has sparked interest in identifying novel soluble factors capable of activating inducible BAT (iBAT) to combat obesity. Using a high content cell-based screen, we identified fibroblast growth factor 16 (FGF16) as a potent inducer of several physical and transcriptional characteristics analogous to those of both “classical” BAT and iBAT. Overexpression of Fgf16 in vivo recapitulated several of our in vitro findings, specifically the significant induction of the Ucp1 gene and UCP1 protein expression in inguinal white adipose tissue (iWAT), a common site for emergent active iBAT. Despite significant UCP1 up-regulation in iWAT and dramatic weight loss, the metabolic improvements observed due to Fgf16 overexpression in vivo were not the result of increased energy expenditure, as measured by indirect calorimetric assessment. Instead, a pattern of reduced food and water intake, combined with feces replete with lipid and bile acid, indicated a phenotype more akin to that of starvation and intestinal malabsorption. Gene expression analysis of the liver and ileum indicated alterations in several steps of bile acid metabolism, including hepatic synthesis and reabsorption. Histological analysis of intestinal tissue revealed profound abnormalities in support of this conclusion. The in vivo data, together with FGF receptor binding analysis, indicate that the in vivo outcome observed is the likely result of both direct and indirect mechanisms and probably involves multiple receptors. These results highlight the complexity of FGF signaling in the regulation of various metabolic processes.
- adipogenesis
- bile acid
- fibroblast growth factor (FGF)
- fibroblast growth factor receptor (FGFR)
- intestinal metabolism
- metabolism
Footnotes
-
↵* All authors are or were Amgen employees and thus have an actual or perceived conflict of interest with the contents of this article.
- Received August 10, 2016.
- Revision received December 22, 2016.
- © 2017 by The American Society for Biochemistry and Molecular Biology, Inc.











